News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,828 Results
Type
Article (8059)
Company Profile (142)
Press Release (478626)
Multimedia
Podcasts (5)
Webinars (6)
Section
Business (166754)
Career Advice (303)
Deals (25749)
Drug Delivery (7)
Drug Development (52820)
Employer Resources (14)
FDA (9759)
Job Trends (8576)
News (238112)
Policy (17888)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (491)
Accelerated approval (27)
ADA (18)
Adcomms (1)
Allergies (100)
Alliances (33148)
ALS (115)
Alzheimer's disease (989)
Antibody-drug conjugate (ADC) (300)
Approvals (10424)
Artificial intelligence (346)
ASCO (161)
Autoimmune disease (230)
Automation (30)
Bankruptcy (263)
Belgium (3)
Best Places to Work (6957)
BIO (37)
Biologics (20)
BIOSECURE Act (1)
Biosimilars (121)
BioSpace Insights (17)
Biotechnology (90)
Bispecific (5)
Bladder cancer (140)
Brain cancer (33)
Breast cancer (524)
Cancer (3843)
Cardiovascular disease (230)
Career advice (242)
Career pathing (1)
CAR-T (183)
CDC (1)
CDMO (25)
Celiac Disease (1)
Cell therapy (499)
Cervical cancer (35)
Clinical research (48131)
Collaboration (1311)
Commercialization (8)
Compensation (1580)
Complete response letters (35)
COVID-19 (766)
CRISPR (65)
C-suite (823)
Cystic fibrosis (87)
Data (6022)
Denatured (4)
Depression (108)
Dermatology (83)
Diabetes (367)
Diagnostics (4229)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (163)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (172)
Earnings (73796)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88276)
Executive appointments (722)
Eye disease (1)
FDA (12560)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (19)
Frontotemporal dementia (24)
Funding (974)
Gene editing (127)
Generative AI (11)
Gene therapy (340)
GLP-1 (300)
Government (945)
Grass and pollen (2)
Guidances (281)
Healthcare (9365)
Hematology (94)
HIV (55)
Huntington's disease (23)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (72)
Immunology and inflammation (112)
Immuno-oncology (63)
Indications (170)
Infectious disease (960)
Inflammatory bowel disease (131)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (267)
Interviews (41)
IPO (12392)
IRA (2)
Job creations (1968)
Job search strategy (232)
JPM (2)
Kidney cancer (17)
Kidney disease (55)
Layoffs (60)
Legal (5194)
Licensing (27)
Liver cancer (46)
Longevity (21)
Lung cancer (555)
Lung diease (8)
Lymphoma (262)
Machine learning (29)
Management (3)
Manufacturing (591)
Marketing (9)
MASH (118)
Medical affairs (2)
Medical device (8690)
Medtech (8855)
Mergers & acquisitions (14436)
Metabolic disorders (743)
mRNA (70)
Multiple sclerosis (107)
Multispecific (1)
NASH (4)
Netherlands (1)
Neurodegenerative disease (230)
Neuropsychiatric disorders (40)
Neuroscience (1893)
NextGen: Class of 2026 (3151)
Non-profit (843)
Obesity (235)
Opinion (10)
Ovarian cancer (172)
Pain (181)
Pancreatic cancer (215)
Parkinson's disease (212)
Partnered (12)
Patents (512)
Patient advocacy (1)
Patient recruitment (534)
Patient selection (16)
Peanut (33)
People (41419)
Peptides (6)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15557)
Phase 2 (21508)
Phase 3 (14507)
Pipeline (7971)
Policy (18)
Postmarket research (1563)
Preclinical (6563)
Press Release (34)
Prostate cancer (196)
Psychedelics (9)
Radiopharmaceuticals (199)
Rare diseases (613)
Real estate (3023)
Recruiting (6)
Regenerative medicine (8)
Regulatory (15054)
Reports (23)
Research institute (587)
Resumes & cover letters (45)
Rett syndrome (44)
RNA editing (7)
RSV (48)
Schizophrenia (104)
Series A (170)
Series B (125)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (91)
Sponsored (5)
Startups (2021)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (52)
The Weekly (1)
Vaccines (324)
Venture capital (17)
Weight loss (76)
Wet AMD (1)
Women's health (92)
Date
Today (97)
Last 7 days (393)
Last 30 days (1423)
Last 365 days (19146)
2026 (14403)
2025 (19240)
2024 (22989)
2023 (26544)
2022 (34587)
2021 (37164)
2020 (33479)
2019 (23242)
2018 (17470)
2017 (18746)
2016 (17920)
2015 (24263)
2014 (21676)
2013 (18136)
2012 (20222)
2011 (20440)
2010 (20332)
Location
Africa (229)
Alabama (80)
Alaska (2)
Arizona (314)
Arkansas (12)
Asia (18007)
Australia (2111)
California (12561)
Canada (3292)
China (557)
Colorado (509)
Connecticut (436)
Delaware (219)
Europe (24743)
Florida (1888)
Georgia (396)
Hawaii (3)
Idaho (46)
Illinois (744)
India (55)
Indiana (327)
Iowa (16)
Japan (439)
Kansas (104)
Kentucky (33)
Louisiana (27)
Maine (27)
Maryland (1249)
Massachusetts (8221)
Michigan (316)
Minnesota (580)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (125)
New Hampshire (60)
New Jersey (2751)
New Mexico (12)
New York (2947)
North Carolina (1328)
North Dakota (4)
Northern California (6329)
Ohio (299)
Oklahoma (14)
Oregon (16)
Pennsylvania (2337)
Puerto Rico (24)
Rhode Island (30)
South America (407)
South Carolina (79)
South Dakota (1)
Southern California (5236)
Tennessee (126)
Texas (2059)
United States (40695)
Utah (378)
Vermont (1)
Virginia (160)
Washington D.C. (39)
Washington State (968)
West Virginia (1)
Wisconsin (78)
Wyoming (1)
486,828 Results for "chemocentryx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
Amgen continues to defend Tavneos as global regulatory pressure mounts
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
July 10, 2026
·
4 min read
·
Nick Paul Taylor
Press Releases
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
October 1, 2026
·
2 min read
Deals
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI).
October 20, 2022
·
14 min read
Business
ChemoCentryx Announces Changes to its Board of Directors
ChemoCentryx, Inc., announced changes to the composition of its Board of Directors.
May 31, 2022
·
4 min read
Deals
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.
August 4, 2022
·
16 min read
Business
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET.
August 9, 2022
·
7 min read
Biotech Bay
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan).
May 31, 2022
·
8 min read
Business
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022.
July 5, 2022
·
4 min read
Business
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
ChemoCentryx, Inc., announced financial results for the first quarter ended March 31, 2022 and provided an overview of recent corporate highlights.
May 5, 2022
·
16 min read
Business
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022.
August 2, 2022
·
2 min read
1 of 48,683
Next
